Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cingulate Inc ( (CING) ) just unveiled an announcement.
Between March 31, 2025, and July 21, 2025, Cingulate Inc. issued several securities exempt from registration under the Securities Act of 1933. These transactions included issuing common stock to a service provider and a lender, as well as an option award to an officer, reflecting strategic financial maneuvers to manage debt and incentivize key personnel.
The most recent analyst rating on (CING) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
Cingulate Inc.’s overall stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, such as securing a grant and progress towards FDA approval, provide a positive outlook. The technical analysis shows neutral momentum, but valuation remains a concern due to financial losses and lack of dividends.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Cingulate Inc. operates in the pharmaceutical industry, focusing on developing and commercializing innovative treatments for central nervous system disorders.
Average Trading Volume: 159,583
Technical Sentiment Signal: Hold
Current Market Cap: $27.64M
For a thorough assessment of CING stock, go to TipRanks’ Stock Analysis page.